HCV: The Journey from Discovery to a Cure

Volume II

  • Michael J. Sofia

Part of the Topics in Medicinal Chemistry book series (TMC, volume 32)

Table of contents

  1. Front Matter
    Pages i-viii
  2. HCV NS5A Inhibitors

  3. HCV NS4B Inhibitors

    1. Front Matter
      Pages 157-157
    2. Giuseppe Manfroni, Rolando Cannalire
      Pages 159-183
  4. Clinical Trials and Combination Therapy

    1. Front Matter
      Pages 185-185
    2. Viviana Figueroa Diaz, Mary Olson, Ira M. Jacobson
      Pages 187-235
    3. Anu Osinusi, John G. McHutchison
      Pages 237-280
    4. Diana M. Brainard, John G. McHutchison
      Pages 281-315
    5. Daniel E. Cohen
      Pages 347-367
    6. Michael N. Robertson, Eliav Barr
      Pages 369-407
  5. Impact of Curative Therapies

    1. Front Matter
      Pages 409-409
    2. Michael W. Fried, David R. Nelson
      Pages 411-427
    3. Marianne Martinello, Behzad Hajarizadeh, Jason Grebely, Gail V. Matthews, Gregory J. Dore
      Pages 447-490
    4. Michael J. Sofia
      Pages 491-495
  6. Back Matter
    Pages 497-500

About this book


​Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide.

This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume I".


NS5B Inhibitors NS4B Inhibitors HCV Combination Therapy DAA therapies Pharmacoeconimics HCV Clinical Trials Vaccine Development

Editors and affiliations

  • Michael J. Sofia
    • 1
  1. 1.Arbutus Biopharma, Inc.WarminsterUSA

Bibliographic information

  • DOI
  • Copyright Information Springer Nature Switzerland AG 2019
  • Publisher Name Springer, Cham
  • eBook Packages Chemistry and Materials Science
  • Print ISBN 978-3-030-28399-5
  • Online ISBN 978-3-030-28400-8
  • Series Print ISSN 1862-2461
  • Series Online ISSN 1862-247X
  • Buy this book on publisher's site